Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction

Coronary Artery Disease

Volumn 20, Issue 6, 2009, Pages 415-421

  Rasoul, Saman ^a   Ottervanger, Jan Paul ^a   De Boer, Menko Jan ^a   Dambrink, Jan Henk E ^a   Hoorntje, Jan C A ^a   Marcel Gosselink, A T ^a   Zijlstra, Felix ^b   Suryapranata, Harry ^a   Van 't Hof, Arnoud W J ^a  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

30 day outcome; Long term outcome; Percutaneous coronary intervention; ST elevation myocardial infarction

Indexed keywords

AGED; ARTICLE; BLOOD CLOT LYSIS; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

AGE FACTORS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DIABETES COMPLICATIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 69549103794     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32832e5c4c     Document Type: Article

References (43)

1. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328:680-684. (Pubitemid 23073369)
2. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328:673-679.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13-20. (Pubitemid 36050955)
4. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336:847-860. (Pubitemid 27132984)
5. ISIS-1 (First International Study of Infarct Survival) Collaborative Study Group. Randomized trial of intravenous atenolol among (16 027) cases of suspected acute myocardial infarction. Lancet 1986; 2:57-65.
6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al.; the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
7. Hennekens C, Albert C, Godfried SL, Gazizno JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction evidence from clinical trials. N Engl J Med 1996; 335:1660-1667.
8. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349:1498-1504.
9. Mehta RH, O'Neill WW, Harjai KJ, Cox DA, Brodie BR, Boura J, et al.; Primary Angioplasty In Myocardial Infarction (PAMI) and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. Am J Cardiol 2006; 97:817-822.
10. De Boer MJ, Reiber JHC, Suryapranata H, van den Brand MJBM, Hoorntje JCA, Zijlstra F. Angiographic findings and catheterisation laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction. Eur Heart J 1995; 16:1347-1356.
11. De Bondt P, De Winter O, Vandenberghe S, Vandevijver F, Segers P, Bleukx A, et al. Accuracy of commercially available processing algorithms for planar radionuclide ventriculography using data for a dynamic left ventricular phantom. Nucl Med Commun 2004; 25:1197-1202. (Pubitemid 39614282)
12. Waldecker B, Waas W, Haberbosch W, Voss R, Heizmann H, Tillmanns H. Long-term follow-up after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32:1320-1325. (Pubitemid 28522389)
13. Califf RM, Pieper KS, Lee KL, Van De Werf F, Simes RJ, Armstrong PW, Topol EJ. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101:2231-2238. (Pubitemid 30317123)
14. Lee CH, van Domburg RT, Hoye A, Lemos PA, Tanabe K, Smits PC, et al. Predictors of survival after contemporary percutaneous coronary revascularization for acute myocardial infarction in the real world. J Invasive Cardiol 2004; 16:627-631. (Pubitemid 39532108)
15. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S-12S.
16. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562. (Pubitemid 26154241)
17. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764. (Pubitemid 27387202)
18. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ. Prevalence of high blood pressure and elevated serum creatinine level in the United States. Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161:1207-1216.
19. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165:923-928. (Pubitemid 40563240)
20. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-546.
21. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964.
22. Jacoby R, Nesto R. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992; 20:736-744.
23. Aronson D, Rayfield E, Cheseboro J. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997; 126:296-306. (Pubitemid 27078778)
24. Toabi A, Cleland JGF, Khan NK, Loh PH, Clark AL, Alamgir F, et al. The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 2008; 29:859-870.
25. Abraham WT, Bristow MR. Specialized centers for heart failure management. Circulation 1997; 96:2755-2757. (Pubitemid 27500062)
26. Opie LH, Hesse B. Radionuclide tracers in the evaluation of resting myocardial ischemia and viability. Eur J Nucl Med 1997; 24:1183-1193. (Pubitemid 27435030)
27. Jneid H, Thacker HL. Coronary artery disease in women: different, often under-treated. Cleve Clin J Med 2001; 68:441-448. (Pubitemid 32422502)
28. Vaccarino V, Parsons L, Every NR, for the National Registry of Myocardial Infarction 2 Participants. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999; 341:217-225.
29. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109:1223-1225. (Pubitemid 38372780)
30. Thiele H, Kappl MJ, Linke A, Erbs S, Boudriot E, Lembcke A, et al. Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. Eur Heart J 2007; 28:1433-1439.
31. Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Buonamici P, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2002; 89:1248-1252. (Pubitemid 34606883)
32. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104:636-641. (Pubitemid 32738515)
33. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292:362-366. (Pubitemid 38944261)
34. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36:1202-1209. (Pubitemid 30760583)
35. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130:239-243.
36. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93:1993-1999. (Pubitemid 26167228)
37. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397-1405. (Pubitemid 40615609)
38. Webb JG, Sleeper LA, Buller CE, Boland J, Palazzo A, Buller E, et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction a report from the SHOCK Trial Registry, SHould we emergently revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol 2000; 36:1084-1090. (Pubitemid 30681573)
39. Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol 2001; 37:1757-1764.
40. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction the CAPRICORN randomised trial. Lancet 2001; 357:1385-1390. (Pubitemid 32455364)
41. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
42. Hohnloser SH, Gersh BJ. Changing late prognosis of acute myocardial infarction impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator. Circulation 2003; 107:941-946. (Pubitemid 36258714)
43. Ottervanger JP, Ramdat Misier AR, Zijlstra F, Schalij MJ, Wever E, Jordaens LJ, et al.; DAPA Investigators. Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) trial. Am Heart J 2006; 152:636-640.